Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

No therapeutic agent is currently approved for the treatment of SARSCoV-2 infection. More importantly, no intervention is currently available to mitigate the progression of disease from mid

  • 0 views
  • 22 Apr, 2021
  • 3 locations
Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19

This study is a randomized, double-blind, multicenter, placebo-controlled trial to evaluate the safety and efficacy of a novel therapeutic agent, Novaferon, in hospitalized adult patients

  • 0 views
  • 31 Jul, 2021
  • 4 locations
Immune Modulators for Treating COVID-19

ACTIV-1 IM is a master protocol designed to evaluate multiple investigational agents for the treatment of moderately or severely ill patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The research objectives are to evaluate each agent with respect to speed of recovery, mortality, illness severity, and hospital resource …

  • 0 views
  • 11 Jul, 2021
  • 85 locations
Evaluation of Safety of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

Patients with mild cognitive impairment due to Alzheimer's disease (MCI due to AD) are at high risk to develop Alzheimers dementia. The therapeutic agent Contraloid has the potential to

  • 0 views
  • 02 May, 2021
  • 1 location
Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis

therapeutic agent for cardiac sarcoidosis. In the current study, researchers aim to evaluate the safety and efficacy of IL-1 blockade with anakinra (IL-1 receptor antagonist) in patients with cardiac

  • 2 views
  • 26 Jan, 2021
  • 2 locations
MIBG Therapy for Patients With MIBG Avid Tumors

. <131>I-MIBG was subsequently used as an therapeutic agent for these tumor types. Phase I and II therapeutic trials targeting neuroblastoma have reported response rates of 10-50%. Toxicities

  • 2 views
  • 03 Jun, 2021
  • 1 location
Atezolizumab and BCG in High Risk BCG na ve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)

deliver high local concentrations of a therapeutic agent within the bladder, potentially destroying viable tumor cells that remain following TURBT. Although the exact mechanism of bacillus Calmette-Guerin

carcinoma
bacillus calmette-guerin
bladder cancer
carcinoma in situ
tumor cells
  • 0 views
  • 25 Jan, 2021
5% Lidocaine-medicated Plaster for the Treatment of Trigeminal Neuralgia

patients with TN may not achieve adequate pain relief with a single therapeutic agent. Multiple analgesics targeting different mechanisms of the pain pathway are often used.5% lidocaine medicated plaster

analgesic
ache
pain relief
neurological examination
  • 0 views
  • 28 Jul, 2021
  • 1 location
An Open Label Registry Study of Lutetium-177 (DOTA0 TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours

Lu-DOTA-TATE (Lutetium-177 octreotate) is a radiopharmaceutical that has been reported as being effective in controlling symptoms and increase quality of life; induce stable disease and extend progression free survival; induce a (good) partial remission and induce a complete remission in patients with a somatostatin receptor positive tumour. The purpose of …

somatostatin
neuroendocrine tumor
dotatate
lu-dota-tate
  • 63 views
  • 26 Jan, 2021
  • 1 location
Ghrelin in Cystic Fibrosis

Background to ghrelin Ghrelin is a naturally occurring hormone found in the blood which stimulates appetite. In healthy individuals, levels of ghrelin are high before a meal and falls afterwards. Previous studies have shown that giving ghrelin (by injection) to thin patients with renal failure and cancer increases their food …

cancer
genetic disorder
pulmonary function test
  • 9 views
  • 07 Nov, 2020
  • 1 location